AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox
NCT ID NCT07678619
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a new AI-powered toolkit designed to help public health officials at local CDC offices respond more quickly to emerging infectious diseases such as COVID-19, mpox, influenza, and dengue. The toolkit combines data analysis, risk assessment, decision support, and evaluation tools. Around 780 CDC staff across five Chinese provinces will use the toolkit alongside their usual methods, and their response times will be compared to those who follow routine practices only.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SMART-ID Toolkit (AI-driven decision-support software)
- What this could lead to
- If successful, this AI toolkit could help public health officials respond to outbreaks faster and more effectively, potentially saving lives during future epidemics.
- What could go wrong
- This is a relatively small, early-stage study in five Chinese provinces. The toolkit may not work as well in other regions or with different diseases, and real-world effectiveness remains unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AVIAN INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jue Liu
Beijing, Beijing Municipality, 100191, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?